Wellington Management Group LLP Takes $333,000 Position in Corvus Pharmaceuticals, Inc. $CRVS

Wellington Management Group LLP purchased a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 104,872 shares of the company’s stock, valued at approximately $333,000. Wellington Management Group LLP owned approximately 0.15% of Corvus Pharmaceuticals as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the business. American Century Companies Inc. raised its holdings in shares of Corvus Pharmaceuticals by 103.9% in the 1st quarter. American Century Companies Inc. now owns 89,265 shares of the company’s stock valued at $284,000 after purchasing an additional 45,491 shares in the last quarter. Towerview LLC raised its holdings in shares of Corvus Pharmaceuticals by 64.5% in the 1st quarter. Towerview LLC now owns 127,500 shares of the company’s stock valued at $405,000 after purchasing an additional 50,000 shares in the last quarter. Cannon Global Investment Management LLC bought a new stake in shares of Corvus Pharmaceuticals in the 1st quarter valued at about $111,000. Oppenheimer & Co. Inc. raised its holdings in shares of Corvus Pharmaceuticals by 24.9% in the 1st quarter. Oppenheimer & Co. Inc. now owns 22,534 shares of the company’s stock valued at $72,000 after purchasing an additional 4,490 shares in the last quarter. Finally, Masso Torrence Wealth Management Inc. raised its holdings in shares of Corvus Pharmaceuticals by 16.7% in the 1st quarter. Masso Torrence Wealth Management Inc. now owns 35,000 shares of the company’s stock valued at $111,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Stock Up 6.1%

NASDAQ CRVS opened at $5.74 on Tuesday. The firm has a market cap of $427.69 million, a PE ratio of -5.68 and a beta of 0.51. The company has a 50 day moving average price of $4.56 and a 200 day moving average price of $4.05. Corvus Pharmaceuticals, Inc. has a 52 week low of $2.54 and a 52 week high of $10.00.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.03. On average, equities research analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current fiscal year.

Insider Transactions at Corvus Pharmaceuticals

In other Corvus Pharmaceuticals news, Director Peter A. Thompson sold 1,176,332 shares of the company’s stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $4.16, for a total transaction of $4,893,541.12. Following the transaction, the director owned 7,165,006 shares in the company, valued at approximately $29,806,424.96. This represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 31.30% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on CRVS shares. Oppenheimer restated an “outperform” rating and issued a $17.00 price target (up previously from $15.00) on shares of Corvus Pharmaceuticals in a report on Friday, May 9th. Mizuho set a $11.00 price objective on shares of Corvus Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, May 20th. Finally, Wall Street Zen upgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $15.00.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.